WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561659
CAS#: 55242-55-2
Description: Propentofylline is a phosphodiesterase inhibitor with neuroprotective effect. It was studied for the treatment of Alzheimer's disease and multi-infarct dementia, as well as its action as an adenosine reuptake inhibitor.
Hodoodo Cat#: H561659
Name: Propentofylline
CAS#: 55242-55-2
Chemical Formula: C15H22N4O3
Exact Mass: 306.17
Molecular Weight: 306.360
Elemental Analysis: C, 58.81; H, 7.24; N, 18.29; O, 15.67
Synonym: Propentofylline; Hextol; Karsivan; Propentophylline; HWA-285; HWA 285; HWA285;
IUPAC/Chemical Name: 3-Methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione
InChi Key: RBQOQRRFDPXAGN-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3
SMILES Code: O=C(N1CCCCC(C)=O)N(C)C2=C(N(CCC)C=N2)C1=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 306.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Sahoo AK, Dandapat J, Dash UC, Kanhar S. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease. J Ethnopharmacol. 2017 Dec 14. pii: S0378-8741(17)32077-9. doi: 10.1016/j.jep.2017.12.015. [Epub ahead of print] Review. PubMed PMID: 29248451.
2: Nijs J, Loggia ML, Polli A, Moens M, Huysmans E, Goudman L, Meeus M, Vanderweeën L, Ickmans K, Clauw D. Sleep disturbances and severe stress as glial activators: key targets for treating central sensitization in chronic pain patients? Expert Opin Ther Targets. 2017 Aug;21(8):817-826. doi: 10.1080/14728222.2017.1353603. Epub 2017 Jul 12. Review. PubMed PMID: 28685641.
3: Walters ET. Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense. Exp Neurol. 2014 Aug;258:48-61. doi: 10.1016/j.expneurol.2014.02.001. Review. PubMed PMID: 25017887.
4: Hirota T, Kishi T. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophr Res. 2013 Sep;149(1-3):88-95. doi: 10.1016/j.schres.2013.06.038. Epub 2013 Jul 18. Review. PubMed PMID: 23870805.
5: Mika J, Zychowska M, Popiolek-Barczyk K, Rojewska E, Przewlocka B. Importance of glial activation in neuropathic pain. Eur J Pharmacol. 2013 Sep 15;716(1-3):106-19. doi: 10.1016/j.ejphar.2013.01.072. Epub 2013 Mar 13. Review. PubMed PMID: 23500198.
6: Landry RP, Jacobs VL, Romero-Sandoval EA, DeLeo JA. Propentofylline, a CNS glial modulator does not decrease pain in post-herpetic neuralgia patients: in vitro evidence for differential responses in human and rodent microglia and macrophages. Exp Neurol. 2012 Apr;234(2):340-50. doi: 10.1016/j.expneurol.2011.11.006. Epub 2011 Nov 15. Review. PubMed PMID: 22119425.
7: Sweitzer S, De Leo J. Propentofylline: glial modulation, neuroprotection, and alleviation of chronic pain. Handb Exp Pharmacol. 2011;(200):235-50. doi: 10.1007/978-3-642-13443-2_8. Review. PubMed PMID: 20859798.
8: Narita M, Suzuki M, Kuzumaki N, Miyatake M, Suzuki T. Implication of activated astrocytes in the development of drug dependence: differences between methamphetamine and morphine. Ann N Y Acad Sci. 2008 Oct;1141:96-104. doi: 10.1196/annals.1441.032. Review. PubMed PMID: 18991953.
9: Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep. 2008 May-Jun;60(3):297-307. Review. PubMed PMID: 18622054.
10: Pantoni L. Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. J Neurol Sci. 2004 Nov 15;226(1-2):67-70. Review. PubMed PMID: 15537523.
11: Bath PM, Bath-Hextall FJ. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database Syst Rev. 2004;(3):CD000162. Review. PubMed PMID: 15266424.
12: Frampton M, Harvey RJ, Kirchner V. Propentofylline for dementia. Cochrane Database Syst Rev. 2003;(2):CD002853. Review. PubMed PMID: 12804440.
13: Wilkinson D. Drugs for treatment of Alzheimer's disease. Int J Clin Pract. 2001 Mar;55(2):129-34. Review. PubMed PMID: 11321852.
14: Rathbone MP, Middlemiss PJ, Gysbers JW, Andrew C, Herman MA, Reed JK, Ciccarelli R, Di Iorio P, Caciagli F. Trophic effects of purines in neurons and glial cells. Prog Neurobiol. 1999 Dec;59(6):663-90. Review. PubMed PMID: 10845757.
15: Ringheim GE. Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia. Ann N Y Acad Sci. 2000 Apr;903:529-34. Review. PubMed PMID: 10818548.
16: Schubert P, Morino T, Miyazaki H, Ogata T, Nakamura Y, Marchini C, Ferroni S. Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann N Y Acad Sci. 2000 Apr;903:24-33. Review. PubMed PMID: 10818485.
17: Bath PM, Bath FJ, Asplund K. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database Syst Rev. 2000;(2):CD000162. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD000162. PubMed PMID: 10796310.
18: Winblad B, Wimo A. Assessing the societal impact of acetylcholinesterase inhibitor therapies. Alzheimer Dis Assoc Disord. 1999 Nov;13 Suppl 2:S9-19. Review. PubMed PMID: 10622674.
19: van Reekum R, Simard M, Farcnik K. Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairment. Can Fam Physician. 1999 Apr;45:945-52. Review. PubMed PMID: 10216793; PubMed Central PMCID: PMC2328342.
20: Kapl D, Rudolphi KA. [New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)]. Tierarztl Prax Ausg K Kleintiere Heimtiere. 1998 Sep;26(5):317-21. Review. German. PubMed PMID: 9931990.